MCID: DND018
MIFTS: 41

Dendritic Cell Tumor

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Dendritic Cell Tumor

MalaCards integrated aliases for Dendritic Cell Tumor:

Name: Dendritic Cell Tumor 20 58
Dendritic Cell Neoplasm 20 70
Dendritic Cell Sarcoma, Not Otherwise Specified 70

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C96.4
Orphanet 58 ORPHA98289
UMLS 70 C1301364 C1531553

Summaries for Dendritic Cell Tumor

GARD : 20 A dendritic cell tumor develops from the cells of the immune system. This condition typically begins in the lymph system and may spread to nearby organs or distant parts of the body ( metastasize ). There are five subtypes of dendritic cell tumors: follicular dendritic cell tumor, interdigitating dendritic cell tumor, Langerhans' cell histiocytosis, Langerhans' cell sarcoma, and dendritic cell sarcoma not specified otherwise. The symptoms and severity of the condition depend on the subtype and location of the tumor. Treatment may include surgery, radiation therapy, and/or chemotherapy.

MalaCards based summary : Dendritic Cell Tumor, also known as dendritic cell neoplasm, is related to rare tumor and parapharyngeal meningioma. An important gene associated with Dendritic Cell Tumor is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and Cytoskeletal Signaling. The drugs Bevacizumab and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and spleen, and related phenotypes are hematopoietic system and immune system

Related Diseases for Dendritic Cell Tumor

Diseases related to Dendritic Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 rare tumor 30.7 FSCN1 FCER2 CR2 ACTC1
2 parapharyngeal meningioma 30.4 CR2 CR1
3 follicular dendritic cell sarcoma 30.4 FCER2 CR2 CR1 CD68
4 myeloid sarcoma 30.4 PTPRC MPO DNTT CD68
5 interdigitating dendritic cell sarcoma 30.2 FSCN1 CR2 CR1 CD1A
6 angiosarcoma 30.0 VIM MUC1 CD68
7 fibrous histiocytoma 30.0 VIM S100B CD68 ACTC1
8 leprosy 3 30.0 IFNG CD68 CD1A
9 histiocytosis 30.0 S100B PTPRC IFNG CD207 CD1A
10 lymphoma, hodgkin, classic 29.9 PTPRC FSCN1 CD68
11 lymphoblastic lymphoma 29.8 PTPRC MPO DNTT
12 b-lymphoblastic leukemia/lymphoma 29.8 PTPRC MPO DNTT
13 myelodysplastic syndrome 29.7 MPO IFNG DNTT CR1 CD69 CD68
14 reticulosarcoma 29.7 PTPRC MUC1 FSCN1 CD68
15 hemangioma 29.7 VIM MUC1 CD68 ACTC1
16 merkel cell carcinoma 29.5 PTPRC MUC1 KRT20 DNTT
17 leiomyosarcoma 29.5 VIM S100B MUC1 ACTC1
18 meningioma, familial 29.5 VIM S100B MUC1 CD68
19 langerhans cell histiocytosis 29.5 S100B PTPRC IFNG FSCN1 CD68 CD207
20 malignant peripheral nerve sheath tumor 29.5 VIM S100B MUC1 ACTC1
21 castleman disease 29.4 S100B IFNG FSCN1 FCER2 CR2 CR1
22 sarcoma, synovial 29.4 VIM S100B MUC1
23 malignant fibrous histiocytoma 29.3 VIM S100B PTPRC MUC1 CD68 ACTC1
24 spindle cell sarcoma 29.3 VIM S100B NCOA2 MUC1 ACTC1
25 chondrosarcoma 29.1 VIM S100B NCOA2 MUC1
26 inflammatory myofibroblastic tumor 29.0 VIM S100B MUC1 FCER2 CR2 CR1
27 skin disease 28.9 VIM S100B MPO IFNG FCER2 CD1A
28 indeterminate cell histiocytosis 11.4
29 histiocytic and dendritic cell tumor 11.2
30 leukemia, acute lymphoblastic 10.6
31 myeloid leukemia 10.5
32 acute leukemia 10.5
33 capillary leak syndrome 10.5
34 lymphangiectasis 10.4 VIM ACTC1
35 primitive neuroectodermal tumor of the cervix uteri 10.4 VIM PTPRC
36 intravascular papillary endothelial hyperplasia 10.4 VIM ACTC1
37 glomangiomyoma 10.4 VIM ACTC1
38 retroperitoneal fibrosis 10.4 VIM PTPRC
39 benign metastasizing leiomyoma 10.4 VIM ACTC1
40 congenital epulis 10.4 VIM CD68
41 epulis 10.4 VIM CD68
42 cobblestone retinal degeneration 10.4 PTPRC CD68
43 diphtheria 10.4
44 endobronchial leiomyoma 10.4 CR2 CR1
45 multicentric reticulohistiocytosis 10.3 VIM CD68
46 small intestinal sarcoma 10.3 PTPRC CD68
47 thrombocytopenia 10.3
48 rhinoscleroma 10.3 CD68 CD1A
49 angiolipoma 10.3 VIM ACTC1
50 glomangioma 10.3 VIM ACTC1

Graphical network of the top 20 diseases related to Dendritic Cell Tumor:



Diseases related to Dendritic Cell Tumor

Symptoms & Phenotypes for Dendritic Cell Tumor

MGI Mouse Phenotypes related to Dendritic Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 ACTC1 CD207 CD68 CD69 CR2 DNTT
2 immune system MP:0005387 9.4 CD207 CD68 CD69 CR2 DNTT FCER2

Drugs & Therapeutics for Dendritic Cell Tumor

Drugs for Dendritic Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2 Vaccines Phase 3
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4
Sodium citrate Approved, Investigational Phase 2 68-04-2
5
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
6
Racepinephrine Approved Phase 2 329-65-7 838
7
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
8
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
9
Tamoxifen Approved Phase 2 10540-29-1 2733526
10
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
13
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
15
Idarubicin Approved Phase 2 58957-92-9 42890
16
leucovorin Approved Phase 2 58-05-9 6006
17
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
18
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
19
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
21
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
22
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
23
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
24
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
25
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
26
Daunorubicin Approved Phase 2 20830-81-3 30323
27
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
28
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
29
Mercaptopurine Approved Phase 2 50-44-2 667490
30
Ichthammol Approved Phase 2 8029-68-3
31
rituximab Approved Phase 2 174722-31-7 10201696
32
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
33
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
34
Pembrolizumab Approved Phase 2 1374853-91-4
35
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
36
Imiquimod Approved, Investigational Phase 2 99011-02-6 57469
37
nivolumab Approved Phase 2 946414-94-4
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
39
Creatine Approved, Investigational, Nutraceutical Phase 1, Phase 2 57-00-1 586
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
42
Cortisone Experimental Phase 2 53-06-5 222786
43
Molgramostim Investigational Phase 1, Phase 2 99283-10-0
44 Epinephryl borate Phase 2
45 Citrate Phase 2
46 Albumin-Bound Paclitaxel Phase 2
47 Anesthetics Phase 2
48 Estrogens Phase 2
49 Estrogen Receptor Antagonists Phase 2
50 Estrogen Antagonists Phase 2

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial Recruiting NCT04277221 Phase 3
2 Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic Completed NCT00499083 Phase 2 aromatase inhibition therapy;cyclophosphamide;doxorubicin hydrochloride;paclitaxel;tamoxifen citrate
3 SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Completed NCT02113982 Phase 1, Phase 2 SL-401
4 The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma Completed NCT00626860 Phase 1, Phase 2
5 Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03599960 Phase 2 Chemotherapy
6 A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies Recruiting NCT03386513 Phase 1, Phase 2 IMGN632
7 A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT04109482 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
8 Tagraxofusp (SL-401) Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation Recruiting NCT04317781 Phase 2
9 Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX Recruiting NCT04216524 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin;Mercaptopurine;Methotrexate;Methylprednisolone;Prednisone;Venetoclax;Vincristine
10 A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT03404193 Phase 2 Decitabine;Venetoclax
11 A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting NCT03316573 Phase 2 Pembrolizumab
12 Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Active, not recruiting NCT00458536 Phase 1, Phase 2 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
13 Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With GM-CSF and Imiquimod Active, not recruiting NCT00799110 Phase 2 GM-CSF;imiquimod
14 Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia Not yet recruiting NCT04342962 Phase 2 tagraxofusp
15 Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) Terminated NCT03075553 Phase 2
16 Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 Terminated NCT00622401 Phase 1, Phase 2 Interleukin-12;Interleukin-12
17 Vaccination With Dendritic Cell/Tumor Fusions in Conjunction With Autologous Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT00458653 Phase 1
18 The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma Completed NCT00459069 Phase 1
19 Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03485547 Phase 1 Venetoclax
20 Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS) Recruiting NCT03113643 Phase 1 Azacitidine;SL-401;Venetoclax
21 Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
22 Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Terminated NCT03203369 Phase 1
23 Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population: A Multicenter Study Completed NCT03974971
24 Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN): a Retrospective Study of Patients Diagnosed in France From 2000 to 2013 Completed NCT02859623

Search NIH Clinical Center for Dendritic Cell Tumor

Genetic Tests for Dendritic Cell Tumor

Anatomical Context for Dendritic Cell Tumor

MalaCards organs/tissues related to Dendritic Cell Tumor:

40
Myeloid, T Cells, Spleen, Bone Marrow, Lymph Node, Colon, Salivary Gland

Publications for Dendritic Cell Tumor

Articles related to Dendritic Cell Tumor:

(show top 50) (show all 658)
# Title Authors PMID Year
1
Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms. 61
33676766 2021
2
Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. 61
33739343 2021
3
Mutational analysis in different foci revealing the clonal evolution of blastic plasmacytoid dendritic cell neoplasm. 61
33174506 2021
4
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. 61
32241840 2021
5
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. 61
33795208 2021
6
A Very Rare Type of Leukemia in a Young Pediatric Patient Treated With Hematopoietic Stem Cell Transplantation: Blastic Plasmacytoid Dendritic Cell Neoplasm. 61
33235146 2021
7
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. 61
32871587 2021
8
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. 61
33687433 2021
9
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. 61
33161793 2021
10
Dermoscopy of blastic plasmacytoid dendritic cell neoplasm in two patients. 61
33639013 2021
11
Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms. 61
33598264 2021
12
Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report. 61
33530792 2021
13
Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review. 61
32852895 2021
14
Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy. 61
33707837 2021
15
Primary cutaneous blastic plasmacytoid dendritic cell neoplasm in a child: A challenging diagnosis and management. 61
33275310 2021
16
Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition. 61
33324955 2021
17
Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. 61
33392975 2021
18
Specific cutaneous infiltrates in patients with haematological neoplasms: a retrospective study with 49 patients. 61
33403659 2021
19
Acute leukemia as the initial presentation of blastic plasmacytoid dendritic cell neoplasm. 61
32880935 2021
20
Spontaneous Regression of Blastic Plasmacytoid Dendritic Cell Neoplasm Following Sepsis by Serratia marcescens: A Case Report and Literature Review. 61
33716255 2021
21
Blastic plasmacytoid dendritic cell neoplasm in a young patient. 61
33560790 2021
22
MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. 61
33405278 2020
23
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant). 61
32902339 2020
24
Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm. 61
32968828 2020
25
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. 61
32111969 2020
26
Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study. 61
32278799 2020
27
A Case Series of Blastic Plasmacytoid Dendritic Cell Neoplasia. 61
33457326 2020
28
Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. 61
32917576 2020
29
Blastic Plasmacytoid Dendritic-Cell Neoplasm. 61
33252872 2020
30
Blastic plasmacytoid dendritic cell neoplasm with a history of cytopenia: A case report. 61
32374950 2020
31
Indeterminate Dendritic Cell Tumor as Cutaneous Involvement of Chronic Myelomonocytic Leukemia Successfully Treated With Phototherapy. 61
32568837 2020
32
Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine. 61
33167311 2020
33
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. 61
33027528 2020
34
CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. 61
33113953 2020
35
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia. 61
32692611 2020
36
Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. 61
32955827 2020
37
Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. 61
32770556 2020
38
Blastic plasmacytoid dendritic cell neoplasm. A rare hematodermic malignancy. 61
31926915 2020
39
[Dendritic cell tumor vaccine assisted by Tiaohengfang polysaccharides enhances immune function of S180 tumor-bearing mice and inhibits tumor growth]. 61
33148385 2020
40
[Clinicopathological characteristics of indeterminate dendritic cell tumor of four cases]. 61
32892557 2020
41
Targeting CD123 in AML. 61
32862874 2020
42
CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia? 61
32970810 2020
43
Descriptive Analysis of Histiocytic and Dendritic Cell Neoplasms: A Single-Institution Experience. 61
32882761 2020
44
Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. 61
32366145 2020
45
Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review. 61
32830878 2020
46
Blastic Plasmacytoid Dendritic Cell Neoplasm: An Uncommon Entity to Consider in the Differential Diagnosis of Cutaneous Lymphoma. 61
32054364 2020
47
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review. 61
32847479 2020
48
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. 61
32841341 2020
49
Blastic Plasmacytoid Dendritic Cell Neoplasm: Underlining the importance of an early diagnosis and the use of tagraxofusp therapy before wide dissemination. 61
32757292 2020
50
[Progress in diagnosis and treatment of pediatric blastic plasmacytoid dendritic-cell neoplasm]. 61
32842395 2020

Variations for Dendritic Cell Tumor

Expression for Dendritic Cell Tumor

Search GEO for disease gene expression data for Dendritic Cell Tumor.

Pathways for Dendritic Cell Tumor

GO Terms for Dendritic Cell Tumor

Cellular components related to Dendritic Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.28 VIM PTPRC MUC1 MPO FSCN1 FCER2

Biological processes related to Dendritic Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.56 VIM MUC1 FSCN1 FCER2
2 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.4 IFNG FCER2
3 regulation of regulatory T cell differentiation GO:0045589 9.37 IFNG CR1
4 complement activation, alternative pathway GO:0006957 9.32 CR2 CR1
5 complement receptor mediated signaling pathway GO:0002430 9.16 CR2 CR1
6 positive regulation of killing of cells of other organism GO:0051712 8.96 IFNG FCER2
7 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.62 PTPRC FCER2

Sources for Dendritic Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....